These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 24744302)

  • 1. The risk of seizures among the carbapenems: a meta-analysis.
    Cannon JP; Lee TA; Clark NM; Setlak P; Grim SA
    J Antimicrob Chemother; 2014 Aug; 69(8):2043-55. PubMed ID: 24744302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative review of the carbapenems.
    Zhanel GG; Wiebe R; Dilay L; Thomson K; Rubinstein E; Hoban DJ; Noreddin AM; Karlowsky JA
    Drugs; 2007; 67(7):1027-52. PubMed ID: 17488146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is it safe to use carbapenems in patients with a history of allergy to penicillin?
    Sodhi M; Axtell SS; Callahan J; Shekar R
    J Antimicrob Chemother; 2004 Dec; 54(6):1155-7. PubMed ID: 15486083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epileptogenic potential of carbapenem agents: mechanism of action, seizure rates, and clinical considerations.
    Miller AD; Ball AM; Bookstaver PB; Dornblaser EK; Bennett CL
    Pharmacotherapy; 2011 Apr; 31(4):408-23. PubMed ID: 21449629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurotoxicity of carbapenem antibacterials.
    Norrby SR
    Drug Saf; 1996 Aug; 15(2):87-90. PubMed ID: 8884160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher rates of carbapenem-related seizures in older hospitalised adults.
    Neo HY; Tan KT; Caroline C; Wei-Han Ng D; Pei-Ying Ho E; Lim JP; Hsien-Xiong Lee R; Choon-Kiat Tan N; Chien-Boon Lye D; Ding YY
    Intern Med J; 2020 Jan; 50(1):123-127. PubMed ID: 31943613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Retrospective Study on the Incidence of Seizures among Neurosurgical Patients Who Treated with Imipenem/Cilastatin or Meropenem.
    Wu Y; Chen K; Shi Z; Wang Q
    Curr Pharm Biotechnol; 2014; 15(8):685-90. PubMed ID: 25051950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carbapenems: past, present, and future.
    Papp-Wallace KM; Endimiani A; Taracila MA; Bonomo RA
    Antimicrob Agents Chemother; 2011 Nov; 55(11):4943-60. PubMed ID: 21859938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial.
    Nakane T; Tamura K; Hino M; Tamaki T; Yoshida I; Fukushima T; Tatsumi Y; Nakagawa Y; Hatanaka K; Takahashi T; Akiyama N; Tanimoto M; Ohyashiki K; Urabe A; Masaoka T; Kanamaru A;
    J Infect Chemother; 2015 Jan; 21(1):16-22. PubMed ID: 25239059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carbapenems in serious infections: a risk-benefit assessment.
    Norrby SR
    Drug Saf; 2000 Mar; 22(3):191-4. PubMed ID: 10738843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants.
    Hornik CP; Herring AH; Benjamin DK; Capparelli EV; Kearns GL; van den Anker J; Cohen-Wolkowiez M; Clark RH; Smith PB;
    Pediatr Infect Dis J; 2013 Jul; 32(7):748-53. PubMed ID: 23838776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Empiric carbapenem monotherapy in pediatric bone marrow transplant recipients.
    Nelson WK; Rayback PA; Quinones R; Giller RH
    Ann Pharmacother; 2002 Sep; 36(9):1360-5. PubMed ID: 12196052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients.
    Kuo BI; Fung CP; Liu CY
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):361-7. PubMed ID: 10862445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carbapenems versus other beta-lactams in the treatment of hospitalised patients with infection: a mixed treatment comparison.
    Edwards SJ; Clarke MJ; Wordsworth S; Welton NJ
    Curr Med Res Opin; 2009 Jan; 25(1):251-61. PubMed ID: 19210156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbapenems: a potent class of antibiotics.
    Nicolau DP
    Expert Opin Pharmacother; 2008 Jan; 9(1):23-37. PubMed ID: 18076336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of seizure-inducing potential of doripenem.
    Zhanel GG; Ketter N; Rubinstein E; Friedland I; Redman R
    Drug Saf; 2009; 32(9):709-16. PubMed ID: 19670912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem.
    Riera E; Cabot G; Mulet X; García-Castillo M; del Campo R; Juan C; Cantón R; Oliver A
    J Antimicrob Chemother; 2011 Sep; 66(9):2022-7. PubMed ID: 21653605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics.
    Horiuchi M; Kimura M; Tokumura M; Hasebe N; Arai T; Abe K
    Toxicology; 2006 May; 222(1-2):114-24. PubMed ID: 16549226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Purchase of carbapenems in Vietnam, a low- to middle-income pharmaceutical market with a high burden of antimicrobial drug resistance.
    Quynh NTN; Dat VQ
    WHO South East Asia J Public Health; 2021; 10(1):12-17. PubMed ID: 35046152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of carbapenem versus non-carbapenem treatment on the rates of superinfection: A meta-analysis of randomized controlled trials.
    Eljaaly K; Enani MA; Al-Tawfiq JA
    J Infect Chemother; 2018 Nov; 24(11):915-920. PubMed ID: 30197092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.